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Abstract The most frequent mutant variant of the cystic ¢bro-
sis transmembrane conductance regulator (CFTR), vF508-
CFTR, is misprocessed and subsequently degraded in the endo-
plasmic reticulum. Using the patch-clamp technique, we showed
that co-expressions of vF508-CFTR with the N-terminal CFTR
truncates containing bi-arginine (RXR) retention/retrieval mo-
tifs result in a functional rescue of the vF508-CFTR mutant
channel in COS-1 cells. This vF508-CFTR rescue process was
strongly impaired when truncated CFTR constructs possessed
either the vF508 mutation or arginine-to-lysine mutations in
RXRs. In conclusions, our data demonstrated that expression
of truncated CFTR constructs could be a novel promising ap-
proach to improve maturation of vF508-CFTR channels.
. 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Cystic ¢brosis (CF) is a fatal genetic disorder that results
from mutations in a gene encoding the cAMP-activated chlo-
ride channel known as the cystic ¢brosis transmembrane con-
ductance regulator (CFTR) [1^3]. The most frequent mutation
identi¢ed in CF patients is a deletion of the phenylalanine
codon at position 508 (vF508) that causes misprocessing
and subsequent degradation of the mutant protein in the en-
doplasmic reticulum (ER) [4^7]. Although some of the ER
chaperones that are involved in CFTR processing have been
identi¢ed [8^12], it is still unknown how the ER quality con-
trol mechanism discriminates between correct and mutated
CFTR. Conditions that a¡ect protein folding such as high
glycerol concentration or reduced temperature result in rescue
of the vF508-CFTR mutant, which can reach the cell surface
and forms a functional, cAMP-activated chloride channel [13^
15]. The processing defect of vF508-CFTR can also be par-
tially suppressed by second-site mutations in the nucleotide
binding domain 1 (NBD1) [16^18], however, the molecular
mechanism of this intragenic suppression still remains unclear.
Four putative ER retention/retrieval signals have been iden-
ti¢ed in the ¢rst half of CFTR [19]. These tripeptide RXR
motifs are composed of two arginines (R) that are separated
by any amino acid (X) and are homologues of the RKR motif
responsible for the ER retention/retrieval in the KATP channel
assembly [20]. The RXR motifs of CFTR are localized in the
N-terminal tail (R29Q30R31), in NBD1 (R516Y517R518 and
R553A554R555) and the regulatory (R) domain (R764R765R766)
(Fig. 1A). Arginine-to-lysine mutations in RXRs of vF508-
CFTR result in the appearance of a functional channel in the
plasma membrane, suggesting that these motifs are responsi-
ble for interaction of the nascent chain with as yet unidenti¢ed
components of the ER quality control system [19].
Here we show that transient co-expression of vF508-CFTR
with truncated CFTR polypeptides in COS-1 cells results in a
remarkable increase of cAMP-activated chloride current, in-
dicating a functional rescue of vF508-CFTR channels most
likely as an e¡ect of destabilization and/or saturation of the
ER quality control system by truncated CFTR chains. These
vF508-CFTR-dependent currents are strongly impaired when
the truncated constructs possess either vF508 or arginine-to-
lysine mutations of RXR motifs in NBD1, suggesting that the
vF508 mutation may interfere with recognition of CFTR
RXRs by the ER quality control system.
2. Materials and methods
2.1. DNA constructs and site-directed mutagenesis of RXR motifs
The bicistronic pCINeo/IRES-green £uorescent protein (GFP) vec-
tors expressing either CFTR, vF508-CFTR or MDR1 have been de-
scribed in detail elsewhere [21^24].
All the CFTR and vF508-CFTR truncation constructs are sche-
matically represented in Fig. 1. The WF1 construct expressing 177
amino acids (aa) from the N-terminal part of CFTR was ampli¢ed
by polymerase chain reaction (PCR), using the oligonucleotides 5P-
CTAGCTAGCGACCCCAGCGCCCGAGAGACC (NheI site under-
lined) and 5P-CCGCTCGAGCTAACTTATTTTATCTAGAACACG
(XhoI site underlined; in-frame stop codon in bold) and the pCINeo/
IRES-GFP/CFTR vector as a DNA template. The obtained PCR
fragment was digested with NheI and XhoI and cloned back into
the NheI- and XhoI-cut pCINeo/IRES-GFP/CFTR vector.
The N-terminal half-size versions of CFTR and vF508-CFTR that
comprise the complete NBD1 (for determination of the N- and C-ter-
minal boundaries of NBD1 see [25]), WF2 and MF2 were constructed
as follows. The 1097 bp fragment corresponding to the region between
V272 and L636 was PCR-ampli¢ed, using the oligonucleotides 5P-
CTGTTAAGGCATACTGCTGGGAAGAAGC and 5P-CGGAAT
TCTACTCGAGTAGATTTTGGAGTTCTGAAAATGTCCC (Eco-
RI site underlined; in-frame stop codon in bold) and the pCINeo/
IRES-GFP/CFTR (for WF2) or pCINeo/IRES-GFP/vF508-CFTR
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(for MF2) vector as a DNA template. After digestion with CelII and
EcoRI, the obtained PCR fragments were cloned into CelII- and
EcoRI-cut pCINeo/IRES-GFP/CFTR.
The RR1 and RR2 fragments expressing 129 aa of NBD1 were
ampli¢ed by PCR, using the oligonucleotides 5P-CTAGCTAGC
CACCATGGTGATTATGGGAGAACTGGAG (NheI site under-
lined; in-frame ATG codon in bold) and 5P-GCGAATTCCTAATC-
ATCGAGGTTAGCCATCAGTTTACAGAC (EcoRI site under-
lined; in-frame stop codon in bold) and pCINeo/IRES-GFP/CFTR
(for RR1) or pCINeo/IRES-GFP/MR2-7 (for RR2) as a DNA tem-
plate. NheI- and EcoRI-digested PCR products were cloned into the
respective restriction sites in the pCINeo/IRES-GFP vector.
The site-directed mutagenesis of arginine residues in RXR motifs of
truncated CFTR constructs was performed using the standard PCR
overlap extension technique as previously described [26]. The base
pair substitutions (underlined) were introduced using following oligo-
nucleotides: for R29K mutation: 5P-GAAAGGATACAAACAGC-
GCCTGGA (sense) and 5P-TCCAGGCGCTGTTTGTATCCTTTC
(antisense); for R516K mutation: 5P-CTATGATGAATATAAATA-
CAGAAGCGTC (sense) and 5P-GACGCTTCTGTATTTATATTC-
ATCATAG (antisense); for R555K mutation: 5P-GGTCAACGAG-
CAAAAATTTCTTTAGC (sense) and 5P-GCTAAAGAAATTTT-
TGCTCGTTGACC (antisense). To amplify 5P and 3P PCR products
that overlap with a mutated residue, two separate PCRs were per-
formed, using the respective sense and antisense mutagenic oligonu-
cleotides in pair with the outermost oligonucleotides used for ampli-
¢cation of WF1 and WF2 constructs (see oligonucleotide sequences
above) and pCINeo/IRES-GFP/CFTR as a DNA template. The ob-
tained PCR fragments were mixed together and used in the second
step PCR, yielding full-length mutant products. In the last step, these
mutated fragments from the second step PCR were cloned into the
pCINeo/IRES-GFP vector by the strategies used for generation of
WF1- and WF2-expressing vectors. The double and triple mutant
constructs were generated consequently in vectors with single muta-
tions of RXRs in the truncated CFTR.
The absence of additional mutations in all PCR-ampli¢ed DNA
fragments used in this study was always veri¢ed by sequence analysis.
2.2. Cell culture and DNA transfection
Cultured African green monkey kidney ¢broblast cells (cell line
COS-1), obtained from the American Type Culture Collection, were
grown in Dulbecco’s modi¢ed Eagle’s medium containing 10% fetal
calf serum, 2 mmol/ml L-glutamine, 2 U/ml penicillin and 2 mg/ml
streptomycin at 37‡C in a fully humidi¢ed atmosphere of 10% CO2 in
air. The cells were detached by exposure to 0.05% trypsin in a Ca2þ-
and Mg2þ-free solution, reseeded on gelatin-coated coverslips, and
kept in culture for 2^4 days before use. Only the non-con£uent cells
were used for the patch-clamp method.
COS-1 cells were transiently co-transfected with pCINeo/IRES-
GFP vectors containing the respective DNA constructs, using Trans-
IT0-COS Transfection Reagent (Mirus, Madison, WI, USA). For
each co-transfection experiment, equal amounts of both vector
DNAs were mixed together at the same transfection cocktail.
Twenty-four hours after transfection, the cells were trypsinized and
seeded on gelatin-coated coverslips and used for electrophysiological
measurement within 2^4 days. The transfected cells were visually iden-
ti¢ed in the patch-clamp setup by the presence of the GFP expression
that was coupled with expression of the respective constructs in the
bicistronic pCINeo/IRES-GFP vector.
2.3. Electrophysiology
The COS-1 cell optimized protocols for solutions and the whole-cell
mode of the patch-clamp technique were used [27]. The extracellular
solution contained (in mM): 150 NaCl, 6 KCl, 1 MgCl2, 1.5 CaCl2,
10 glucose, 10 HEPES; titrated with NaOH to pH 7.4; osmolarity
was 320Q 5 mOsm (vapor pressure osmometer, Wescor 5500, Schlag,
Gladbach, Germany). In all experiments, before the experimental pro-
tocol was started, KCl was replaced by CsCl to block completely the
inwardly rectifying Kþ channel. The CFTR channel was activated by
a cAMP-increasing cocktail containing 100 WM IBMX (3-isobutyl-1-
methylxanthine) and 10 WM forskolin (both from Sigma) dissolved in
isotonic solution. The pipette solution contained (in mM): 20 CsCl,
20 tetraethylammonium chloride, 100 aspartate, 4 EGTA, 4 Mg-ATP,
5 HEPES; titrated to pH 7.2 with CsOH. This solution is slightly
hypotonic (290Q 5 mOsm) in comparison with the standard extracel-
lular solution to prevent spontaneous activation of volume-sensitive
chloride currents.
Coverslips carrying the seeded cells were placed in a recording
chamber mounted on the stage of an Axiovert 10 inverted microscope
(Zeiss). Rapid solution exchange and extracellular application of
drugs were achieved using a multi-barreled pipette connected to solu-
tion reservoirs, and was controlled by a set of magnetic valves. Patch
electrodes were pulled from Vitrex capillary tubes (Modulohm, Her-
lev, Denmark) on a DMZ-Universal puller (Zeitz Instruments, Augs-
burg, Germany). When ¢lled with pipette solution they had a DC
resistance between 2 and 5 M6. An Ag^AgCl wire was used as refer-
ence electrode. Ag^AgCl electrodes of sintered pellets (IVM Systems,
Healdsburg, CA, USA) were used to avoid contamination of the bath
and pipette solutions. Membrane currents were recorded using an
EPC-7 patch-clamp ampli¢er (List Electronic, Lambrecht/Pfalz, Ger-
many) and ¢ltered with an eight-pole Bessel ¢lter (Kemo, Beckenham,
UK). For control of voltage-clamp protocols and data acquisition, we
used the pCLAMP 6 software (Axon Instruments, Foster City, CA,
USA) run on an IBM-compatible PC, which was connected to the
ampli¢er via a TL-1 DMA interface (Axon Instruments). Membrane
currents were measured in the whole-cell mode of the patch-clamp
technique [28]. The cell capacitance and series resistance were assessed
using the analog compensation circuit of the EPC-7 ampli¢er. Gen-
erally, between 50 and 80% of the series resistance was electronically
compensated to minimize voltage errors. A ramp protocol, consisting
of one step to 3100 mV and a 400 ms linear voltage ramp to +100
mV, was applied every 10 or 5 s from a holding potential of 320 mV.
In all experiments, time zero corresponds to the rupture of the mem-
brane. Time courses of the whole-cell currents were measured from
voltage ramps at 380 and +80 mV. Current^voltage relations were
obtained from the currents measured during the linear voltage ramp.
Experiments were performed at room temperature (22^25‡C). Electro-
physiological measurement data were analyzed using the WinASCD
software package (Guy Droogmans, ftp://ftp.cc.kuleuven.ac.be/pub/
droogmans/winascd.zip). Statistical analysis and graphical presenta-
tions were performed using Origin version 7.0 (OriginLab, Northamp-
ton, MA, USA). Pooled data are given as the meanQS.E.M. Signi¢-
cance was calculated using Student’s unpaired t-test and is presented
as asterisks (*P6 0.05).
3. Results
3.1. vF508-CFTR function is restored upon co-expression with
truncated CFTR
Transient expression of vF508-CFTR from the CMV-EI
promoter in COS-1 cells results in the appearance of a signi¢-
cant cAMP-activated Cl3 current (Fig. 2A,E), indicating that
a fraction of the mutant channels escapes the ER quality
control and reaches the cell surface. To evaluate this cellular
model in the context of functional vF508-CFTR rescue, COS-
1 cells transfected with vF508-CFTR were incubated for 24 or
48 h at 26‡C and then used for the patch-clamp method.
Forty-eight hours incubation of the cells at 26‡C resulted in
an almost three-fold increase of Cl3 currents through vF508-
CFTR channels when compared to cells cultured at 37‡C
(231.2 Q 11.4 versus 87.5 Q 6.8 pA/pF). The shorter incubation
(24 h) had a less pronounced e¡ect on the vF508-CFTR chlo-
ride channel function (current densities of 117.5Q 15.8 pA/
pF), demonstrating a correlation between the duration of
the low temperature treatment and levels of the vF508-
CFTR channel rescue.
We tested whether co-expression of vF508-CFTR with
truncated wild type CFTR fragments, which include RXR
motifs, might result in plasma membrane localization and
function of vF508-CFTR channels. We generated GFP vec-
tors with truncated CFTR constructs, WF1 and WF2, which
express the N-terminal 177 and 636 aa fragments of wild type
CFTR, containing one and three RXR motifs, respectively
(Fig. 1B). We did not generate a construct that comprised
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all four RXR motifs (WF2 extended over the R domain)
because this truncated CFTR variant was shown to function
as a cAMP-activated Cl3 channel [29^31].
Co-expression of vF508-CFTR with WF2 in COS-1 cells
results in an almost six-fold increase of cAMP-activated Cl3
current when compared to cells co-transfected with vF508-
CFTR and empty vectors (510.9 Q 79.2 versus 87.5Q 6.8 pA/
pF; Fig. 2I), indicating the presence of functional channels in
the plasma membrane. The density of the current through
vF508-CFTR was similar to current observed in cells that
expressed only wild type CFTR (645.8Q 52.1 pA/pF; Fig.
2I). No signi¢cant di¡erences in time courses, current^voltage
relationships or reversal potentials of these two currents were
observed (Fig. 2C,G and Fig. 2B,F). The presence of WF1 in
vF508-CFTR-expressing cells resulted in a moderate 2.5-fold
increase of cAMP-activated Cl3 current (Table 1). No current
was observed when COS-1 cells were transfected only with
WF2 vector (Fig. 2D,H), ruling out the possibility of recon-
stitution of functional channels by oligomerization of trun-
cated CFTR fragments in the plasma membrane.
3.2. vF508-CFTR function is not e⁄ciently rescued when
co-expressed with the N-terminal half-size vF508-CFTR
construct
Since two RXR motifs are localized in NBD1 of CFTR, we
examined whether vF508 mutation might a¡ect rescue prop-
erties of WF2. The MF2 construct is identical to WF2 except
for the presence of the vF508 mutation (Fig. 1B). cAMP-
activated Cl3 current was almost 2.5-fold reduced in COS-1
cells co-transfected with vF508-CFTR and MF2 vectors when
compared to cells co-expressing vF508-CFTR and WF2
(167.9 Q 29.1 versus 510.9 Q 79.2 pA/pF; Fig. 3). This current
was similar to that observed in cells with vF508-CFTR and
WF1 co-expression (Table 1), suggesting that vF508 interferes
with the accessibility of RXR motifs in NBD1.
3.3. RXRs in NBD1 of truncated CFTR constructs are
essential for e⁄cient rescue of vF508-CFTR function
To determine the role of particular RXRs in the vF508-
CFTR rescue, we created a series of arginine-to-lysine muta-
tions in RXRs of WF1 and WF2 constructs (Fig. 1C). Co-
expression of vF508-CFTR with mutated constructs, possess-
ing R516K and R555K mutations either alone or in combi-
nation, led to an about two-fold decrease of vF508-CFTR-
dependent current when compared to cells that co-expressed
vF508-CFTR and WF2 (Table 1). This suggests that both
RXRs in NBD1 contribute equally to interaction with pro-
teins of the ER system. Surprisingly, the R29K mutation did
not signi¢cantly a¡ect the rescuing properties of WF1 as well
as WF2 (Table 1), suggesting the presence of another reten-
tion/retrieval motif in the N-terminal tail of CFTR.
To further evaluate the role of NBD1 in the vF508-CFTR
rescue process, we constructed RR1 and RR2 vectors, which
expressed 129 aa of the CFTR NBD1 with both RXRs (from
M469 to N597 ; Fig. 1B). The RR2 construct is identical to RR1
except for the presence of R516K and R555K mutations in
RXRs. Co-expression of RR1 with vF508-CFTR resulted in a
signi¢cant 60% increase of cAMP-activated Cl3 current when
compared to cells co-transfected with vF508-CFTR and
empty vectors (146.8 Q 21.3 versus 87.5 Q 6.8 pA/pF; Fig. 4).
This increase of current was not observed when vF508-CFTR
was co-expressed with RR2, demonstrating that RXRs in the
NBD1 fragment are sole determinants of the vF508-CFTR
rescue.
4. Discussion
Although CFTR was identi¢ed almost 13 years ago, no
e⁄cient pharmaceutical treatments or a gene therapy for CF
have been identi¢ed so far [32]. Much e¡ort is focused on the
correction and improvement of the de¢cient maturation of the
vF508-CFTR channel at the ER level. Transient expression of
Fig. 1. Schematic representation of full-length (A), truncated (B)
and RXR-mutated (C) CFTR and vF508-CFTR constructs. The
black circles indicate the localization of the RXR motifs. An empty
circle corresponds to the vF508 mutation. Arginine-to-lysine muta-
tions in RXRs are indicated by diamonds. TMD, transmembrane
domain; NBD, nucleotide binding domain; R domain, regulatory
domain.
Table 1
Mutations of RXRs in truncated CFTR constructs impair their
properties to rescue vF508-CFTR function
Truncated
CFTR construct
Current density
(pA/pF)
n P
WF1 226.5Q 41.4 8 ^
MR1 155.5Q 24.4 6 NS
WF2 510.9Q 79.2 6 ^
MR2-1 495.8Q 105.7 5 NS
MR2-2 267.3Q 44.5 7 0.018
MR2-3 288.7Q 43.6 9 0.019
MR2-4 295.4Q 60.8 8 0.048
MR2-5 266.5Q 48.6 6 0.025
MR2-6 270.6Q 14.2 5 0.025
MR2-7 213.6Q 39.7 8 0.003
vF508-CFTR-dependent current densities were measured at +80 mV
in cells co-transfected with vF508-CFTR and truncated CFTR-ex-
pressing vectors. Values are meansQS.E.M.; n is number of experi-
ments; signi¢cance (P6 0.05) was calculated, using Student’s un-
paired t-test. NS, not signi¢cant.
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vF508-CFTR from either a vector (Fig. 2A,E) or using re-
combinant vaccinia virus in Vero cells [4] results in the ap-
pearance of cAMP-activated Cl3 current, indicating that a
certain pool of the mutant channels can reach the cell surface.
As proposed previously [7], such ine⁄ciency of the ER quality
control may result from saturation of its components by an
increased number of nascent vF508-CFTR chains. Here we
show that co-expression of vF508-CFTR with truncated wild
type CFTR constructs results in functional rescue of vF508-
CFTR channels. This rescue mechanism seems to be exclusive
to truncated CFTR versions since co-expression of vF508-
CFTR with truncated MDR1 did not result in the vF508-
CFTR rescue (data not shown). Most likely, the truncated
CFTR chains compete with full-length vF508-CFTR to inter-
Fig. 2. Co-expression of WF1 or WF2 with vF508-CFTR results in rescue of mutant channel functions. A^D: Time course of CFTR currents
obtained from measurements at +80 mV (¢lled squares) and 380 mV (empty circles) in cells co-transfected with vF508-CFTR and empty vec-
tors (A), with wild type CFTR and empty vectors (B), with vF508-CFTR and WF2 vectors (C) and transfected only with the WF2 vector (D).
E^H: Current^voltage relationships before (a) and after (b) vF508-CFTR activation with the forskolin (10 WM)/IBMX (100 WM) cocktail at
the time indicated by the empty squares in A^D). I: Comparison of vF508-CFTR chloride current densities in cells co-expressing indicated
CFTR and vF508-CFTR constructs. Bars denote meanQS.E.M. Numbers of analyzed cells are indicated. Signi¢cance was calculated using Stu-
dent’s unpaired t-test (***P6 0.001).
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act with components of the ER quality control system. There-
fore, they might be recognized as premature or not fully trans-
lated proteins and subsequently degraded by the ER-associ-
ated protein degradation pathway [33^36]. Concomitantly,
full-length vF508-CFTR chains that lack the interaction in
the ER may bypass quality control and enter the secretory
pathway to the plasma membrane.
Expression of truncated CFTR constructs, WF1, WF2 and
MF2, in the absence of the vF508-CFTR expression vector
does not result in cAMP-activated Cl3 currents (Fig. 2D,H
and data not shown). This is at variance with previously pub-
lished reports, which showed that similar CFTR truncates can
function as cAMP-activated chloride channels in Xenopus oo-
cytes [29,37,38] and IB3-1 cells [29], a human bronchial epi-
thelial cell line derived from a CF patient compound hetero-
zygous for the vF508 mutation (vF508/W1282X) [39]. We
have no explanation for the functional expression of truncated
CFTR versions in Xenopus oocytes. However, it is well de-
scribed that expression of small proteins in Xenopus oocytes
very often induces up-regulation of endogenous Cl3 channels
[40,41]. IB3-1 cells are CF cells. We propose from our results
that the observed cAMP-activated current in IB3-1 cells ex-
pressing truncated CFTR is an e¡ect of functional rescue of
endogenous vF508-CFTR channels. Further experiments will
be focused on the functional rescue of endogenous vF508-
CFTR, using expression of truncated CFTR or arti¢cially
engineered polypeptides.
Each of the truncated CFTR fragments used for vF508-
CFTR rescue contains bi-arginine RXR motifs. Arginine-to-
lysine mutation in NBD1’s RXRs of truncated CFTR con-
structs (R516K and R555K mutations) strongly impairs their
vF508-CFTR rescue properties. Similar results were obtained
when the truncated construct contains vF508 mutation
(MF2), suggesting that this mutation interferes with RXR
accessibility. It has recently been proposed that RXR accessi-
bility could be lost by the assembly of subunits in the ER [42].
The assembled complexes can then be exported from the ER
via the coated protein complex II vesicles. In the ER^Golgi
intermediate compartment (ERGIC) and in the cis-Golgi, cor-
rectly oligomerized proteins are transported towards the plas-
ma membrane while unassembled or partially assembled sub-
units bind to the coated protein complex I (COPI) via RXRs
and are recycled to the ER in COPI vesicles for a next round
of quality control. It should be noted that by default ‘mis-
takes’ of the ER quality control, some unassembled or par-
tially assembled subunits could also escape from the ER.
Based on this mechanism, we propose that the vF508 muta-
tion would create a conformational change in NBD1 of
Fig. 3. vF508 mutation in the MF2 construct strongly impairs res-
cue of the vF508-CFTR channel. A: Time course of CFTR currents
obtained from measurements at +80 mV (¢lled squares) and 380
mV (empty circles) in cells co-transfected with vF508-CFTR and
MF2 vectors. B: The current^voltage relationship before (a) and
after (b) vF508-CFTR activation with the forskolin (10 WM)/IBMX
(100 WM) cocktail at the time indicated by the empty squares in A.
C: vF508-CFTR-dependent current densities from cells co-trans-
fected with vF508-CFTR and either empty (3), WF2 or MF2 vec-
tors. Bars denote meanQS.E.M. Numbers of analyzed cells are indi-
cated. Signi¢cance was calculated using Student’s unpaired t-test
(***P6 0.001).
Fig. 4. Co-expression of vF508-CFTR with the wild type CFTR
NBD1 rescues vF508-CFTR channel function. A,B: Time course of
CFTR currents obtained from measurements at +80 mV (¢lled
squares) and 380 mV (empty circles) in cells co-transfected with
vF508-CFTR and either RR1 (A) or RR2 vectors (B). C,D: Cur-
rent^voltage relationships before (a) and after (b) vF508-CFTR ac-
tivation with the forskolin (10 WM)/IBMX (100 WM) cocktail at the
time indicated by the empty squares in A,B. E: Comparison of
vF508-CFTR-dependent chloride current densities in cells co-trans-
fected with vF508-CFTR and either empty (3), RR1- or RR2-ex-
pressing vectors. Bars denote meanQS.E.M. and numbers of ana-
lyzed cells are indicated. Signi¢cance was calculated using Student’s
unpaired t-test (**P6 0.01).
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CFTR, resulting in constitutive accessibility of RXRs to ER
and/or COPI proteins. Therefore, the majority of vF508-
CFTR is retained and degraded in the ER or, if exported to
the ERGIC, retrotransported to the ER via COPI vesicles and
then degraded. The fact that second-site mutations in NBD1
of vF508-CFTR partially correct processing and functional
defects of this mutant channel strongly supports this latter
hypothesis (note that R553Q and R553M mutations corre-
spond to the arginine in the RAR motif) [16^18].
In conclusion, we show here that expression of short CFTR
polypeptides could be a promising approach to rescue vF508-
CFTR function. Identi¢cation of ER proteins that interact
with RXR motifs of CFTR as well as elucidation of cellular
fates of CFTR truncates will be indispensable to understand
the critical steps of the ER quality control and tra⁄cking of
CFTR channels.
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